The use of physiologically informed fluid and vasopressor resuscitation with passive leg raise–induced stroke volume change is safe for guiding the personalized management of sepsis-associated hypotension and shock.
The FDA has issued an EUA to allow for the use of Propoven 2% Emulsion 100mL to maintain sedation via continuous infusion in patients who require mechanical ventilation in an ICU setting during the COVID-19 pandemic.
Patients with septic shock who were administered antibiotics within an hour of onset had decreased in-hospital mortality rates.
No association existed between obstructive sleep apnea and postoperative delirium after risk adjustment in the context of usual care in the intensive care unit.
The FDA approved the New Drug Application (NDA) for Emerphed (Nexus Pharmaceuticals), a premixed, ready-to-use formulation of ephedrine sulfate.
In patients who are admitted to the ICU for the management of sepsis, the coadministration of hydrocortisone, ascorbic acid, and thiamine was safe and reduced the time to resolution of shock.
The Patient-Reported Outcomes Measurement Information System (PROMIS) assessing physical function and pain interference with computer adaptive tests offers a streamlined, effective approach for measuring self-reported outcomes in patients with chronic low back pain.
Mortality did not differ significantly between patients assigned to no sedation and patients assigned to light sedation with daily interruption in the intensive care unit.